EPO plus radiotherapy does not improve local-regional control in anemic patients with head and neck cancer
the ONA take:
According to a long-term analysis of a study originally published in 2007, researchers have found that the combination of erythropoietin and radiation therapy did not improve local-regional control for anemic patients with head and neck squamous cell carcinoma who receive radiotherapy or chemoradiotherapy.
The 2007 Radiation Therapy Oncology Group (RTOG) 9903 study was an open-label, randomized, phase III trial that evaluated whether the addition of erythropoietin to radiotherapy would improve disease control in anemia patients with head and neck squamous cell carcinoma.
For this long-term analysis, results showed that the local-regional failure rate was 39.4% for patients who received radiotherapy or chemoradiotherapy without erythropoietin compared with 46.2% for patients who received erythropoietin at 5-year follow-up (HR = 1.40). Researchers found no statistically significant differences in 5-year progression-free survival, overall survival, or 5-year distant metastases rate between the two groups.
The findings suggest that erythropoietin should not be utilized in anemic patients with head and neck squamous cell carcinoma.
Combination erythropoietin and radiation therapy did not improve control for anemic patients with head and neck squamous cell carcinoma.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|